MorphoSys extends license agreement with Shionogi
The research will be run by the company’s AbD Serotec unit for three additional years. As per the deal, Shionogi will continue to have the right to use
BioMarin Pharmaceutical and n-Lorem Foundation have entered an early-stage research collaboration and exclusive global licence agreement to develop an investigational antisense oligonucleotide (ASO) therapy for ReNU syndrome.